Welcome to the “Axitinib Research and Education Hub,” a community focused on the advancements and applications of axitinib in cancer therapy. Developed by Pfizer, Axitinib is a potent small molecule tyrosine kinase inhibitor known for significantly inhibiting breast cancer growth in animal models and demonstrating partial responses in clinical trials for renal cell carcinoma (RCC) and other tumor types. Join us to explore the latest research, clinical experiences, and discussions on the potential of Axitinib in oncology.